Zuckerberg and Chan Refocus Philanthropy on AI and Biomedical Science Through Biohub

REDWOOD CITY, Calif. — Mark Zuckerberg and Dr. Priscilla Chan are significantly shifting the direction of their philanthropic work, channeling the majority of their resources into the Chan Zuckerberg Biohub to accelerate discoveries in biomedical science through artificial intelligence.

The billionaire couple, who co-founded the Chan Zuckerberg Initiative (CZI) in 2015, say their focus will now center on building advanced AI models to simulate human cell behavior and better understand how diseases emerge, progress, and might be treated or prevented.

From Broad Philanthropy to Focused Science

For the past decade, the couple’s philanthropy has spanned multiple causes, from education and immigration reform to diversity, equity, and inclusion initiatives. However, Zuckerberg announced this week that their science work — particularly through the Biohub network — had proven to be the most transformative and will now become their primary philanthropic focus.

“I feel like the science work that we’ve done, the Biohub model in particular, has been the most impactful thing that we have done,” Zuckerberg said at an event at the Biohub Imaging Institute in Redwood City, California. “Biohub is going to be the main focus of our philanthropy going forward.”

Biohub, launched in 2016, operates as a collaborative research ecosystem connecting universities and research institutions. It currently has centers in San Francisco, Chicago, and New York, each tackling distinct scientific challenges such as cellular mapping, tissue biology, and immune system behavior.

AI at the Core of Disease Research

The refocused effort will use artificial intelligence to create virtual cell systems — digital models of biological functions that can help scientists simulate how cells interact, mutate, and respond to disease. These systems are expected to offer insights into inflammation, immune responses, and genetic mutations that traditional lab experiments cannot easily capture.

Chan, a pediatrician who once treated children with rare diseases, said her work inspired the shift. “What I wanted more than anything was a way to see what was happening inside their cells — how genetic mutations were expressed and what was breaking down,” she explained. “Until now, that kind of understanding has been out of reach. AI is changing that.”

Major Investment in AI Talent and Infrastructure

The couple also announced that Biohub has acquired the team from EvolutionaryScale, an AI research lab specializing in large-scale life sciences systems. Alex Rives, the company’s co-founder, will join Biohub as its new head of science, overseeing experimental biology, data, and artificial intelligence research.

The financial details of the acquisition were not disclosed, but Biohub’s operating budget is expected to reach around $1 billion annually. Since its founding, the organization has committed roughly $4 billion to scientific research and is projected to double that figure over the next decade.

A Long-Term Commitment to Open Science

Unlike many private research ventures, the Chan Zuckerberg Biohub emphasizes open-source science. All data, software, and research tools it produces are freely available to scientists worldwide, a principle the couple say is key to accelerating global biomedical progress.

Zuckerberg explained that their long-term plan involves developing tools and platforms that can serve the wider scientific community. “We decided that the place we can make the biggest impact is tool development — long-term projects, 10 to 15 years, that take on biological challenges and produce tools other scientists can use,” he said.

Biohub’s projects have already generated significant scientific contributions, including one of the world’s largest single-cell datasets and a comprehensive human cell map. Researchers have also built sensors capable of measuring inflammation in real time within living cells and contributed to studies on rare genetic diseases.

Philanthropy and Public Perception

Zuckerberg and Chan have pledged to donate 99% of their lifetime wealth — derived from Meta Platforms stock — to philanthropic causes. Their renewed focus on science comes amid growing public scrutiny over how billionaires allocate their wealth, particularly following comments from singer Billie Eilish last week urging the wealthy to “give their money away.”

Some critics have questioned CZI’s decision to scale back on social impact programs. Earlier this year, the organization ended several grant programs tied to diversity, equity, inclusion, and immigration advocacy, saying that its priorities had been evolving for years toward scientific advancement.

Zuckerberg and Chan responded that CZI will continue to serve as infrastructure for their scientific initiatives rather than as a standalone social grantmaker. “Going forward, Biohub will be our primary philanthropic effort,” the couple said in a joint statement. “We will continue other philanthropic work, but the Initiative will mainly support our science mission.”

AI and the Future of Biomedical Discovery

Biohub’s ultimate goal is to use AI to digitally model the human body at the molecular, cellular, and genomic levels — a feat that could revolutionize medicine by enabling virtual experiments impossible to conduct in real laboratories. These models would function similarly to large language systems that process massive datasets, except they would analyze biological data to predict disease behavior and therapeutic responses.

Chan emphasized that the goal is to move beyond model organisms to directly impact human health. “We’ve cured diseases in mice, flies, and zebrafish many times,” she said. “Now, we want to ensure biology truly pushes the forefront of medicine for people — and that’s what’s so promising.”

The Biohub network plans to expand its partnerships with universities and global research institutions, aligning with governments and public health agencies to make AI-driven biomedical research more accessible.

As the world faces ongoing public health challenges — from pandemics to chronic illnesses — the Chan Zuckerberg Biohub represents a growing trend among philanthropic science ventures: combining massive computational power with biological insight to accelerate cures that traditional science funding might take decades to achieve.